Global management of brain metastasis from renal cell carcinoma.

Pierrard, Julien;Tison, Thaïs;Grisay, Guillaume;Seront, Emmanuel
(2022) Critical Reviews in Oncology / Hematology — Vol. 171, p. 103600 [1-11] (2022)

Files

PierrardJCritRevOncolHematol2022.pdf
  • Open Access
  • Adobe PDF
  • 1.44 MB
Download

Details

Authors
  • Pierrard, Julienorcid-logoUCLouvain
    Author
  • Tison, Thaïs
    Author
  • Grisay, Guillaume
    Author
  • Seront, Emmanuel
    Author
Abstract
During the last decade, major improvements have been made in the treatment of renal cell carcinoma (RCC) with the development and use of multiple tyrosine kinase inhibitors and immune checkpoint inhibitors. Brain metastases in RCC patients (BM-RCC) is associated with poor outcome and their management represents a challenge for clinicians. In most of case, brain metastases in this context require local intervention such as radiotherapy, stereotactic radiotherapy/stereotactic radiosurgery and whole brain radiation therapy. Despite efficacy in extracranial metastases, systemic therapies have modest antitumoral effect on cerebral lesions. In this review, we highlight the benefits and pitfalls of the available therapies in BM-RCC.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Pierrard, J., Tison, T., Grisay, G., & Seront, E. (2022). Global management of brain metastasis from renal cell carcinoma. Critical Reviews in Oncology / Hematology, 171, 103600 [1-11]. https://doi.org/10.1016/j.critrevonc.2022.103600 (Original work published 2022)